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otrexate and infl iximab. Furthermore, indications are 
preferred in which surgery is thought to be inappropri-
ate. The standard 6-TG dosage should not exceed 25 mg 
daily. Routine laboratory controls are mandatory in short 
intervals. Liver biopsies should be performed after 6–12 
months, three years and then three-yearly accompanied 
by gastroduodenoscopy, to monitor for potential hepa-
totoxicity, including nodular regenerative hyperplasia 
(NRH) and veno-occlusive disease (VOD). Treatment 
with 6-TG must be discontinued in case of overt or his-
tologically proven hepatotoxicity. 
 Copyright © 2006 S. Karger AG, Basel 
 Introduction 
 Infl ammatory bowel disease (IBD) is an umbrella term 
for Crohn’s disease (CD), ulcerative colitis (UC) and in-
determinate colitis (IC). These entities are characterized 
by a chronic intestinal infl ammation of relapsing clinical 
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 Abstract 
 Recently, the suggestion to use 6-thioguanine (6-TG) as 
an alternative thiopurine in patients with infl ammatory 
bowel disease (IBD) has been discarded due to reports 
about possible (hepato) toxicity. During meetings ar-
ranged in Vienna and Prague in 2004, European experts 
applying 6-TG further on in IBD patients presented data 
on safety and effi cacy of 6-TG. After thorough evaluation 
of its risk-benefi t ratio, the group consented that 6-TG 
may still be considered as a rescue drug in stringently 
defi ned indications in IBD, albeit restricted to a clinical 
research setting. As a potential indication for administer-
ing 6-TG, we delineated the requirement for mainte-
nance therapy as well as intolerance and/or resistance to 
aminosalicylates, azathioprine, 6-mercaptopurine, meth-
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course. The aims of therapy are the relief of symptoms, 
the maintenance of clinical remission and prevention of 
complications of disease at an acceptable therapeutic 
risk-benefi t ratio. In CD, thiopurines (azathioprine (AZA) 
and 6-mercaptopurine (6-MP)) represent the fi rst-line 
maintenance drugs for steroid-dependent disease  [1] . 
Methotrexate (MTX) is also effective in this indication, 
at least in patients in whom remission has been achieved 
by this agent. Infl iximab is effective in CD patients refrac-
tory or intolerant to thiopurines or MTX  [2, 3] . Concom-
itant immunosuppression with thiopurines or MTX is 
highly recommended to minimize the immunogenicity of 
infl iximab in the setting of episodic treatment  [4] . In the 
case of maintenance treatment with infl iximab, the ques-
tion of the role of concomitant immunosuppressants 
needs to be answered by more prospective data. In UC, 
5-aminosalicylates (5-ASA) are the drugs of fi rst choice to 
maintain remission in mild disease. In case of intolerance 
or drug resistance, AZA and 6-MP may be administered 
for maintenance of remission and steroid-sparing, respec-
tively  [5, 6] . More recently, induction and maintenance 
of remission with infl iximab in UC patients was demon-
strated in two large trials  [7, 8] . The precise place of inf-
liximab in the treatment of UC patients in daily clinical 
practice has yet to be determined; however, infl iximab 
may become an attractive alternative in UC patients. 
 In recent years, the use of 6-thioguanine (6-TG) has 
been proposed as a rescue drug for AZA and 6-MP in IBD 
patients failing to tolerate or respond to standard thiopu-
rines  [9] . However, this suggestion has been discarded 
since 6-TG has been associated with the development of 
liver abnormalities in IBD patients  [10] . An European 
working group of experts with experience on 6-TG in IBD 
has been constituted in Vienna in August 2004. We con-
sented that 6-TG may still be considered an escape drug 
in strictly defi ned clinical situations in a clinical research 
setting and feel that further research is essential to out-
weigh the potential benefi t of 6-TG to its toxicity profi le. 
Here, we give a short overview of 6-TG literature in IBD 
and present a critical appraisal on 6-TG treatment in IBD 
as concluded from two meetings. 
 Pharmacology of Thiopurines and the 
Emergence of 6-Thioguanine for Treating IBD 
 AZA/6-MP are prodrugs which require bioactivation 
via hypoxanthine phosphoribosyl transferase (HPRT) to 
thiopurine nucleotides (thioinosine monophosphate or 
thioguanosine monophosphate, respectively) ( fi g. 1 ). The 
most important inactivating pathway is the S-methyla-
tion of thiopurines catalyzed by the thiopurine S-methyl-
transferase (TPMT), evidently because of alteration of 
the tautomeric form of the nucleobase. TPMT is involved 
at several steps in the complex metabolism of thiopurines, 
and the principal nucleotide metabolites are all substrates 
for human TPMT with similar kinetic parameters. There-
fore, TPMT activity is inversely related to the accumula-
tion of cellular 6-thioguanine nucleotides (6-TGN) which 
are thought to be the pharmacologically active com-
pounds in cancer therapy  [11] . More recently a further 
mechanism with regard to the immunosuppressive effi -
cacy of thiopurine was proposed. The blockade of Rac1 
activation is mediated via binding of the purine nucleo-
tide 6-thioguanosine triphosphate to Rac1, consequently 
resulting in T cell apoptosis  [12] . A possible advantage of 
 Fig. 1.  Simplifi ed thiopurine metabolism scheme. Azathioprine 
(AZA) is degraded to 6-mercaptopurine (6-MP). Thiopurine meth-
yl transferase (TPMT) methylates 6-MP into 6-methylmercaptopu-
rine (6-MMP). By hypoxanthine phosphoribosyl transferase, 6-MP 
is catalyzed to 6-thioinosine monophosphate (6-TIMP). Via two 
other (including hypoxanthine phosphoribosyl transferase) enzy-
matic steps the 6-thioguanine nucleotides (6-TGN) are ultimately 
generated. These 6-TGN consist of three phosphorylated forms:
6-thioguanosine monophosphate (6-TGMP), 6-thioguanosine di-
phosphate (6-TGDP) and 6-thioguanosine triphosphate (6-TGTP).
6-TIMP and 6-TGN may also be methylated by TPMT leading
to 6-methyl-thioinosine monophosphate (6-MTIMP) and 6-meth-
ylthioguanine nucleotides (6-MTGN), respectively. In a cycle, 
6-TIMP is phosphorylated to 6-thioinosine diphosphate (6-TIDP), 
subsequently to 6-thioinosine triphosphate (6-TITP) and ultimate-
ly back to 6-TIMP due to the inosine triphosphate pyrophosphatase 
(ITPase). When ITPase activity is impaired or lacking, 6-TITP ac-
cumulates. 6-Thioguanine (6-TG) is directly converted in 6-TGN 
but may also be methylated by TPMT leading to 6-methylthiogua-
nine (6-MTG). The enzyme xanthine oxidase inactivates 6-MP by 
the formation of 6-thiouric-acid (6-TUA). Via an enzymatic step 
by guanase, 6-TG is metabolized into thioxanthine which can be 
further degraded into 6-TUA by XO. 
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6-TG administration is the direct conversion into 6-TGN 
( fi g. 1 ) whereas in the case of AZA/6-MP a multi-enzy-
matic bioactivating process is required to ultimately form 
6-TGN. Moreover, since TPMT is involved at several 
metabolic steps ( fi g. 1 ), it was assumed that the impact of 
TPMT is more pronounced using AZA/6MP than 6-TG. 
In the case of TPMT defi ciency it has been clearly shown 
that non-methylators (1 up to 200 Caucasians  [13] ) are at 
risk to develop myelotoxicity under standard dosage of 
AZA/6-MP  [14] . Nevertheless, myelotoxicity has also 
been reported under 6-TG treatment due to inherited 
TPMT defi ciency  [15] . On the other hand, very high 
TPMT activity enhances methylation of 6-MP to 6-meth-
ylmercaptopurine ribonucleotides (6-MMPR) and 6-
MMPR are potent inhibitors of the de novo purine syn-
thesis, thereby participating to the immunosuppressive/
cytostatic potential of AZA/6-MP, in addition to the gen-
erated 6-TGN. Thus, it was proposed that AZA/6-MP is 
a two in one drug whereas 6-TG works predominately via 
formation of 6-TGNs. However, 6-TGNs are also methyl-
ated via TPMT and in vitro investigations indicate that 
methylated 6-TGN inhibit de novo purine synthesis as 
well. Moreover, the formation of methylated metabolites 
(MMPR) is of major interest since recently high levels of 
6-MMPR were associated with dose-dependent AZA/6-
MP-related hepatotoxicity  [16] . Although the underlying 
mechanism is still poorly understood this association was 
repeatedly shown in patients with IBD as well as in chil-
dren with acute lymphoblastic leukemia and 6-MP thera-
py. To this end, mutations of the enzyme inosine triphos-
phatase (ITPase) resulting in alteration of ITPase activity 
have been related with AZA/6-MP adverse drug reactions 
like fl u-like symptoms, rash and pancreatitis  [17] . How-
ever, these data are still a matter of ongoing discussion 
since several contradictory results are published  [18, 19] . 
In the case of 6-TG, ITPase is not relevant since it is not 
involved in the metabolism of 6-TG ( fi g. 1 ). 
 Most of the clinical data on 6-TG stems from studies 
in hematological malignancies. In IBD treatment with 6-
TG was described as early as 1966 in three patients with 
UC. However, medication was discontinued prematurely 
due to intolerable neuro- and hepatotoxicity  [20] . In more 
recent years, 6-TG has been considered an alternative 
treatment option in IBD patients who failed therapy with 
AZA or 6-MP due to refractoriness or intolerance (espe-
cially pancreatitis). In 2001, the benefi t of 6-TG was sug-
gested in a phenotypically distinct group of IBD patients 
who failed to attain disease control with traditional AZA 
and 6-MP therapy despite dose escalation  [21] . These pa-
tients were unable to achieve therapeutic 6-TGN levels 
( 6 235 pmol/8    10 8  red blood cells (RBC)) and developed 
excessive levels of potentially (hepato)toxic 6-MMPR 
upon 6-MP dose escalation. Dubinsky et al.  [21] conduct-
ed an open-label pilot study in 10 of these phenotypically 
distinct CD patients to assess safety, tolerance and effi -
cacy of 6-TG. In seven (70%) of 10 patients response was 
achieved by administering 6-TG. Despite high levels of 
RBC 6-TGN ( 1 1,300 pmol/8    10 8  RBC), patients did not 
develop myelotoxic or hepatotoxic events on a short term. 
Subsequently, several small-scaled uncontrolled open la-
bel studies followed in which AZA or 6-MP intolerant or 
refractory IBD patients were treated with 6-TG  [22–28] . 
The majority of patients (75–87%) were able to tolerate 
6-TG treatment. This was recently confi rmed in a larger 
study of 95 AZA or 6-MP intolerant patients using 6-TG 
for at least 1 year  [29] . The most frequently observed side 
effects were gastrointestinal complaints, general malaise, 
allergic reactions and myelotoxicity. Pancreatitis was re-
ported to be a rare adverse event. The use of 6-TG re-
sulted in clinical improvement in a high percentage of this 
AZA or 6-MP intolerant group. Most recently, the results 
from an internet-based, international, multi-centric ap-
proach summarizing clinical data from 296 patients on 
the 6-TG therapy were shown, representing the largest 
population of IBD patients treated with 6-TG  [30] . In 135 
patients (45.6%) treatment with 6-TG was continued at 
data entry for 93 weeks (range 2–207 weeks). Neverthe-
less, 161 patients stopped treatment due to adverse events 
(44.1%), safety reasons (21.7%) and treatment failure 
(24.4%). Adverse events leading to treatment stop were 
mainly pain, nausea/vomiting, leukopenia and thrombo-
penia but only 7 patients discontinued treatment due to 
laboratory signs of hepatotoxicity, albeit the sensitivity of 
liver function parameters to indicate hepatotoxic side ef-
fects associated with 6-TG is limited. Data from random-
ized, controlled trials aiming to investigate for the safety 
and effi cacy of 6-TG in IBD are not available. 
 Hepatotoxicity of 6-Thioguanine in IBD 
Patients 
 After the aforementioned promising reports, an article 
by Dubinsky et al.  [10] at the end of 2003 reported the 
occurrence of nodular regenerative hyperplasia (NRH) 
of the liver in 16/26 (61.5%) biopsies taken from 111 
 patients treated with 6-TG over a mean period of 9.1 
months. Splenomegaly was reported in 4 of the 111 treat-
ed patients. The authors concluded that since the progres-
sion or reversibility of NRH is unknown 6-TG should not 
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be considered as immunosuppressive therapy in IBD. 
However, it should be stated that approximately 92% of 
the investigated IBD patients had used immunosuppres-
sive medication (AZA or 6MP) before and that liver func-
tion disturbances had occurred in about 40% of them pri-
or to the introduction of 6-TG. Since NRH has been de-
scribed under therapy with AZA as well  [31–38] , the 
causative agent for the histopathological fi ndings is diffi -
cult to determine. Subsequently, the same working group 
published data on histological evaluations of liver biopsies 
from 37 patients, 20 of whom (54.1%) had developed 
NRH under treatment with 6-TG  [39] . The authors rela-
tivised their prior conclusion by stating that patients with-
out therapeutic alternatives and without signs of NRH or 
liver fi brosis should periodically be rebiopsied when con-
tinuing therapy with 6-TG in absence of better therapeu-
tic choices. Data stemming from a collaboration within 
our group confi rmed the high frequency of hepatotoxicity 
in 6-TG-treated patients. In this trial 8/45 patients (17.8%) 
receiving 6-TG in a maximal daily dose 40–80 mg for a 
treatment period of 8–119 weeks showed NRH and in the 
same number of patients equivocal patho-histological 
fi ndings, possibly related to NRH were revealed  [40] . It 
could be demonstrated that magnetic resonance imaging 
(MRI) may serve as a non-invasive technique to detect 
NRH with a sensitivity of 77% and a specifi city of 72% 
 [40] . Data from the online survey demonstrated that 31/60 
(51.7%) liver biopsies of IBD patients treated with 6-TG 
had pathological fi ndings  [30] . In 11/38 (28.9%) patients, 
whose liver samples had been stained with silver reticulin 
probable or defi nite NRH was diagnosed (number needed 
to harm (NNH) 3.5). In another approach, the signifi cance 
of NRH by increasing the hepatic venous pressure gradi-
ent and even causing signifi cant portal hypertension was 
shown in 6 out of 26 IBD patients treated with 6-TG  [41] . 
In contrast, recent data on liver histology of 8 IBD patients 
using low dosages of 6-TG (18–21 mg daily) for a mean 
period of 23 months (16–36 months) revealed no histo-
logical abnormalities  [42] . 
 The exact pathogenesis of NRH remains to be eluci-
dated but it is believed to be caused by disturbances of 
the microcirculation in the portal veins. Some aspects 
need to be emphasized on. As stated above NRH and 
similar hepatotoxic features have been described under 
therapy with AZA as well  [31–38] , albeit less common as 
compared to 6-TG. Based on the lack of comprehensive 
studies an accurate estimation on the frequency of NRH 
under AZA/6-MP treatment in IBD cannot be given. The 
high frequency of hepatotoxicity associated with 6-TG 
doses of 40–80 mg/day may be attributed to the signifi -
cantly enhanced levels of 6-TGN  [42] . Interestingly, 
there is a clear predominance of hepatic lesions in male 
patients which raises the question of a genetic predispo-
sition  [43] . Additional different pharmacokinetic and 
metabolic characteristics or a different fi rst-pass effect 
may play a role as well and future research is needed to 
elucidate these differences. New data from the United 
Kingdom acute lymphoblastic leukemia study suggest 
that hepatotoxicity and portal hypertension associated 
with 6-TG therapy in children may be progressive if es-
sential hepatic architectural changes have occurred, even 
after discontinuation of the drug. However, this report 
is restricted to 6 children and conclusive results from 
adults on the natural course of NRH are missing  [44] . 
 Constitution of a European Working Party on 
6-Thioguanine in IBD 
 A Dutch 6-TG working group was formed after the re-
ports of hepatotoxicity on 6-TG treatment in 2003, in or-
der to combine and discuss data and results of approxi-
mately 350 Dutch patients treated with 6-TG. Recently, 
safety and tolerability data of 95 of these patients were de-
scribed  [29] . Alongside this Dutch working group forma-
tion, an European collaboration was initiated consisting of 
largely university-based hospitals located in Amsterdam 
(representing the Dutch 6-TG working group), Graz, 
Linköping, Munich, Prague, Stuttgart, Wels and Vienna. 
Overall, several hundred patients have been treated with 
6-TG by the members of the European working group. 
 A Critical Appraisal of 6-Thioguanine 
Treatment in IBD 
 A European 6-TG working party formulated the fol-
lowing expert-based guidelines for potential future 6-TG 
administration in IBD. 
 6-Thioguanine may be considered in IBD patients 
with requirement for maintenance therapy as well as in-
tolerance and/or resistance to 5-aminosalicylates, AZA, 
6-MP and MTX without an appropriate option for sur-
gery ( table 1 ). This includes an increased risk of short-
bowel syndrome in patients with small bowel Crohn’s 
disease or poor surgical candidates with increased risks 
of complications. In addition, infl iximab should be ad-
ministered before 6-TG therapy is initiated in IBD pa-
tients, however, at present the precise place of infl iximab 
in the treatment of UC patients is only emerging. The ap-
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plication of 6-TG should be restricted to a clinical research 
setting and only after written informed consent providing 
information on its (hepato)toxic profi le, particularly as 
IBD is an off-label indication of 6-TG use. The informed 
consent procedure stresses the clinical need for close fol-
low-up and monitoring but also allows registration of pa-
tients. The group recommends that 6-TG should be ad-
ministered in a standard dose, not exceeding 25 mg/day. 
In the Netherlands, 6-TG is dosed at 0.3 mg/kg body-
weight resulting in three standard 6-TG dosages of 18, 21 
and 24 mg. When IBD patients had to discontinue the 
previous AZA/6-MP use due to potential TPMT-related 
side effects (e.g. myelotoxicity or hematological abnor-
malities), TPMT defi ciency should be defi nitively exclud-
ed. We recommend that 6-TG should not be used in pa-
tients with one or two mutant TPMT alleles since higher 
6-TGN levels can be expected in spite of dose adjustment 
of thiopurines in these cases. 6-TG has to be withdrawn 
from patients resistant to therapy at the latest 6 months 
after initiation of therapy. A rigorous monitoring must be 
performed in all patients ( table 2 ). The drug has to be dis-
continued in case of a twofold rise of at least one liver 
enzyme if at least possibly related to 6-TG use. The 6-TG 
dose must be discontinued when leukocyte counts are 
 ^  3.5  ! 10 9 /l. The 6-TG dosage must be reduced when 
platelet counts are between 100,000 and 150,000 U/l. If 
platelet counts drop below 100,000 U/l 6-TG administra-
tion has to be stopped. In the latter case, a liver biopsy is 
mandatory as low platelets counts have been associated 
with NRH and portal hypertension. Given the document-
ed sensitivity and specifi city of specifi c MRI imaging  [40] , 
this noninvasive technique could additionally be consid-
ered for investigating patients during 6-TG treatment 
with unexplained laboratory abnormalities. Histological 
evaluation of the liver remains the golden standard for 
hepatotoxicity screening in 6-TG-treated patients. 
 The monitoring for hepatotoxicity must include fi rst 
liver biopsy within 6 and 12 months after the initiation 
of 6-TG therapy. Subsequently, a liver biopsy must be 
performed after 3 years and, then after every 3 years of 
6-TG use. Liver biopsy should be accompanied by gas-
troduodenoscopy. The group did not fi nd consensus on 
taking a liver biopsy before the initiation of 6-TG treat-
ment. The specimens should be evaluated by an experi-
enced pathologist after staining with hematoxylin and eo-
sin, (silver)reticulin and trichrome or optional chromo-
trope aniline blue  [10] . The use of electron microscopy in 
evaluating (early) histological abnormalities is currently 
under investigation. It should be kept in mind that a liv-
er biopsy has a small procedure-related risk of complica-
tions. The administration of 6-TG must be discontinued 
 Table 1. Defi nitions of resistance and intolerance to thiopurines 
Defi nition of resistance
A lack of response defi ned by the inability to reach clinical remis-
sion as evaluated by global clinical assessment and the reduction 
of steroids to a dose of prednisolone or its equivalent ^10 mg/d 
between weeks 12 and 24 after start of treatment with AZA/6-MP 
despite a dosage of AZA 62.0/6-MP 61.0 mg/kg body weight.
Defi nition of intolerance
An adverse event (AE) to thiopurines is defi ned as any reaction, 
side effect, or untoward event that occurs during the course of the 
treatment, whether or not the event is considered drug related. AEs 
will include events reported by the patient, as well as clinically sig-
nifi cant abnormal fi ndings on physical examination or laboratory 
evaluation. A new illness, symptom, or sign, a clinically signifi cant 
laboratory abnormality, or worsening of a pre-existing condition or 
abnormality is considered an AE. A stable chronic conditions such 
as arthritis, which are present prior to clinical trial entry and do not 
worsen, are not considered AEs. Worsening of these conditions are 
AEs.
 
Parameters At which moment?
Complete blood count baseline, 1, 2, 4, 8 and 12 weeks – every 3 months
6-Thioguanine nucleotides optional to check patient compliance 
Alanine aminotranferase baseline, 1, 2, 4, 8 and 12 weeks – every 3 months
Aspartate aminotransferase baseline, 1, 2, 4, 8 and 12 weeks – every 3 months
Alkaline phosphatase baseline, 1, 2, 4, 8 and 12 weeks – every 3 months
Gamma-glutamyl transferase baseline, 1, 2, 4, 8 and 12 weeks – every 3 months
Bilirubin baseline, 1, 2, 4, 8 and 12 weeks – every 3 months
Liver biopsy + gastroduodenoscopy between 6 and 12 months; subsequently,
after 3 years and then every 3 years
C-reactive protein (effi cacy control) baseline, 1, 2, 4, 8 and 12 weeks – every 3 months
 
 Table 2. Flowchart of controls
(informed consent should be signed) 
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in case histological abnormalities are found in the liver 
specimens. The measurement of 6-TGN levels in eryth-
rocytes is only useful for determining patient compliance 
 [45] . Contradictory results have been published about the 
potential teratogenic effects of 6-TG in case reports  [46–
48] . Therefore, the use of 6-TG during pregnancy or lac-
tation should be avoided. 
 Conclusion 
 Low-dose 6-thioguanine may still be considered as a 
rescue drug for maintenance of remission in IBD patients 
failing and/or intolerant to all evidence-based conven-
tional therapies including mesalamine, AZA/6-MP, MTX 
and infl iximab, and in whom surgery is thought to be in-
appropriate. Application has to be restricted to a clinical 
research setting. The reported incidence of nodular regen-
erative hyperplasia related to 6-TG use is of major con-
cern and the number needed to harm equals 3.5. There-
fore, any treatment protocols must include rigorous mon-
itoring with regular liver biopsies. A specifi c MRI may be 
used as a noninvasive pre-biopsy screening tool. Further 
research is warranted before the use of 6-TG is dis-
carded. 
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